Changes in Concomitant Therapy for Weight-related Illness Following Initiation of Weight Loss Pharmacotherapy

Authors: B.C. Agatep, S.L. Charland, V. Herrera, G. Hawk, E.J. Stanek

Concomitant therapy for obesity-related illnesses generally has a low incidence and declines significantly over 6 months after initiating weight-loss pharmacotherapy. Antihypertensive and hypothyroidism therapy appear to follow different patterns, and whether this reflects disease progression, effect of weight-loss therapy, genetics, or other factors warrants further investigation.

Citation: Value in Health, Volume 14, Issue 7, November 2011, Pages A419-A420

Link: http://www.sciencedirect.com/science/article/pii/S1098301511025873?_alid=1839068108&_rdoc=1&_fmt=high&_origin=search&_docanchor=&_ct=2&_zone=rslt_list_item&md5=1b3b54d2404261a86cc23589378407ee